American Society of Hematology

SHERPA: Blue

People

  1. Korde
    Korde
  2. Mailankody
    Mailankody
  3. Lesokhin
    Lesokhin
  4. Hassoun
    Hassoun
  5. Hultcrantz
    Hultcrantz
  6. Giralt
    Giralt
  7. Landau
    Landau
  8. Shah
    Shah
  9. Shah
    Shah
  10. Scordo
    Scordo

Groups

  1. Center for Hematologic Malignancies (99)
  2. Department of Medicine (99)
  3. Hematologic Malignancies, Division of (99)
  4. Myeloma (99)
  5. Survivorship Research (99)
  6. Hematologic Malignancies Research (95)
  7. Bone Marrow Transplant (70)
  8. Sloan Kettering Institute Postdocs (70)
  9. Hematology-Oncology Fellows (66)
  10. CTCR Scholars (62)
Search Within
  1. "Neha Korde"
Formats
  1. Meeting Abstract (89)
  2. Journal Article (9)
  3. Research Letter (1)
Groups
  1. Center for Hematologic Malignancies (99)
  2. Department of Medicine (99)
  3. Hematologic Malignancies, Division of (99)
  4. Myeloma (99)
  5. Survivorship Research (99)
  6. Hematologic Malignancies Research (95)

More Groups

People
  1. Neha Korde (99)
  2. Sham Mailankody (81)
  3. Alexander Lesokhin (77)
  4. Hani Hassoun (71)
  5. Malin Hultcrantz (69)
  6. Sergio Giralt (66)

More People

Years
  1. 2025 (2)
  2. 2024 (21)
  3. 2023 (14)
  4. 2022 (12)
  5. 2021 (5)
  6. 2020 (8)

More Years

Publications
  1. Blood (91)
  2. Blood Advances (8)

Results (99)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Outcomes in frail patients receiving BCMA-directed bispecific antibodies for relapsed/refractory multiple myeloma
    Journal Article

    Adegbite, B.; Tan, C. R.; Shekarkhand, T.; Firestone, R. S.; Jurgens, E. M.; Miller, K.; Lesokhin, A. M.; Shah, G. L.; Korde, N.; Rajeeve, S.; more...
    Blood Advances (2025)

    Fulltext@MSK | Save
  • Restarting teclistamab and talquetamab after prolonged dose delay may not require re–step-up dosing
    Research Letter

    Tan, C. R.; Wang, A.; Nemirovsky, D.; Derkach, A.; Shekarkhand, T.; Hamadeh, I.; Maclachlan, K.; Hultcrantz, M.; Hassoun, H.; Mailankody, S.; more...
    Blood Advances (2025)

    Fulltext@MSK | Save
  • Belantamab mafodotin, nirogacestat and pomalidomide for patients with relapsed/refractory multiple myeloma
    Meeting Abstract

    Hultcrantz, M.; Hassoun, H.; Tan, C. R.; Korde, N.; Lesokhin, A. M.; Hashmi, H.; Maclachlan, K. H.; Rajeeve, S.; Shah, U. A.; Patel, D.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Impact of daratumumab refractoriness on clinical outcomes following CAR T-cell therapy for relapsed/refractory multiple myeloma
    Meeting Abstract

    Rajeeve, S.; Costa, B. A.; Jurgens, E. M.; Nishimura, N.; Farzana, T.; Firestone, R. S.; Miller, K.; Lesokhin, A. M.; Shah, G. L.; Korde, N.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Mutationally enriched regions of the non-coding genome harbor functionally impactful mutations that dysregulate key genes involved in multiple myeloma pathogenesis
    Meeting Abstract

    Blaney, P.; Maclachlan, K. H.; Papadimitriou, M.; Mikulasova, A.; Gagler, D. C.; Braunstein, M. J.; Lahoud, O. B.; Kaminetzky, D.; Wang, Y.; Liu, S.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Daratumumab versus lenalidomide as maintenance therapy in newly diagnosed multiple myeloma- Interim efficacy results of a randomized clinical trial
    Meeting Abstract

    Rajeeve, S.; Derkach, A.; Devlin, S. M.; Santos, J.; Przemielewska, A.; Sood, T.; Maclachlan, K. H.; Hashmi, H.; Tan, C. R.; Korde, N.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • A phase 1b study of step-up dosing with ABBV-383, a B-cell maturation antigen (BCMA) x CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma
    Meeting Abstract

    Mian, H.; Baljevic, M.; Magen, H.; Gatt, M. E.; Mazza, I. A.; Searle, E.; Lichtman, E. I.; McKay, J. T.; Plesner, T.; Rodriguez, C.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Impact of absolute lymphocyte count at pre-apheresis and pre-lymphodepletion on chimeric antigen receptor (CAR)-T therapy outcomes in relapsed refractory multiple myeloma (RRMM)
    Meeting Abstract

    Nishimura, N.; Mailankody, S.; Brown, S.; Devlin, S. M.; Costa, B. A.; Farzana, T.; Jurgens, E. M.; Firestone, R. S.; Nath, K.; Chung, D. J.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Immune-MRD status informs tumor-MRD outcome prognostication in multiple myeloma patients on lenalidomide maintenance
    Meeting Abstract

    Firestone, R. S.; Simhal, A. K.; McAvoy, D.; Jurgens, E. M.; Garcés, J. J.; Nemirovsky, D.; Derkach, A.; Maclachlan, K. H.; Hultcrantz, M.; Mailankody, S.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • A high-fiber dietary intervention (NUTRIVENTION) in precursor plasma cell disorders improves biomarkers of disease and may delay progression to myeloma
    Meeting Abstract

    Shah, U. A.; Cogrossi, L. L.; Derkach, A.; Castro, F.; Fei, T.; DeWolf, S.; Garces, J. J.; Policastro, A.; Grioni, M.; Sisti, S.; more...
    Blood (2024)

    Fulltext@MSK | Save